DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD) announced today that it has received conditional approval from the U.S. Food and Drug Administration (FDA) to begin its Impella®2.5 Circulatory Support System study in the United States under an investigational device exemption (IDE) for hemodynamically unstable patients undergoing a percutaneous coronary intervention (PCI) procedure due to acute myocardial infarction (AMI), commonly referred to as heart attack. This approval is conditional upon the Company’s submission of additional information to the FDA over the next 45 days.